Bostongene Announces $150 Million Series B Funding At A Multi-Billion Dollar Valuation, Propelling The Company To Unicorn Status
Bostongene Announces $150 Million Series B Funding At A Multi-Billion Dollar Valuation, Propelling The Company To Unicorn Status
04/06/22, 1:00 PM
Location
walthamMoney raised
$150 million
Round Type
series b
BostonGene today announced the completion of the $150 million Series B funding. NEC Corporation (NEC; TSE: 6701) led the financing with participation from Impact Investment Capital and Japan Industrial Partners. The capital will be used to scale BostonGene’s growth, including continued innovation, clinical and research partnerships, and international expansion. Further, leveraging NEC’s robust infrastructure, BostonGene and NEC intend to form a joint venture to bring lifesaving solutions to patients in Japan and other Asian countries.
Company Info
Location
waltham, massachusetts, united states
Additional Info
BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.